ADVERTISEMENT

Manufacturing

Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches

Amgen Reinvests Sales Gains In R&D As Phase II MariTide Readout Approaches

Amgen’s product sales grew 24% to $8.15bn in Q3 and its gains are being reinvested in R&D and manufacturing, including for MariTide, which will report Phase II obesity data in late 2024.

CRN Appeals To US Supplement Industry For ‘Promoting A More Responsible Industry’

CRN Appeals To US Supplement Industry For ‘Promoting A More Responsible Industry’

In first of two articles from recent interview, president and CEO Steve Mister discusses examples the trade group provides for self-regulation, “where people or companies who might not do it on their own because it would put them at a disadvantage if they were the only ones.”

China Innovation, Large Market Continue To Lure Foreign Investment

China Innovation, Large Market Continue To Lure Foreign Investment

High patient needs, a large healthcare market and innovation potential in the biotech sector in China still appear to be maintaining and attracting investments by overseas biopharma companies, including by Bayer and Lilly in biotech start-ups and Lilly in manufacturing.

Strides To Arm GLP-1 Generics Ahead Of LoEs, As Novo Spars Over Semaglutide Capacity

Strides To Arm GLP-1 Generics Ahead Of LoEs, As Novo Spars Over Semaglutide Capacity

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting.

As Novo Spars Over Semaglutide Capacity, Strides To Arm GLP-1 Generics Cos Ahead Of LoEs

As Novo Spars Over Semaglutide Capacity, Strides To Arm GLP-1 Generics Cos Ahead Of LoEs

Strides is to supply semaglutide and liraglutide to generics companies amid global capacity constraints and drug shortages, ahead of loss of exclusivity. An ability to make drug-device combinations has meant it has contracts for seven of the eight GLP-1 agonists, and counting

From PhD To Unicorn: Mammoth CEO On Pharma Deals and Squishy Biology

From PhD To Unicorn: Mammoth CEO On Pharma Deals and Squishy Biology

Trevor Martin talked to In Vivo about the importance of sharing a strategic vision with partners, the company’s superpower, and how a PhD is the best prep for a startup.

Decentralized Manufacturing Sponsors Must ‘Do Their Homework’ To Impress US & EU Regulators

Decentralized Manufacturing Sponsors Must ‘Do Their Homework’ To Impress US & EU Regulators

Decentralized manufacturing methods for cell and gene therapies will be critical for improving patient access to treatments, but sponsors must prepare to demonstrate “comparability” with centralized manufacturing.

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

US FDA’s Petition Procedures No Place For OTC Acetaminophen Pediatric Dosing Enforcement

Requests for “enforcement actions are not within the scope of FDA’s citizen petition procedures,” CDER says, rejecting petition dosing device firm Parenteral Technologies submitted as it prepares for workshop on Pediatric Research Equity Act requirements for OTC NDA sponsors.

US Nutrition Market People News: CRN/Radicle Award, Nourish, VSI, LabConnect, Akita, More

US Nutrition Market People News: CRN/Radicle Award, Nourish, VSI, LabConnect, Akita, More

CRN/Radicle Trailblazing Woman Award to ChromaDex’s Yasmeen Nkrumah-Elie; Nourish’s TV ad campaign features US soccer star Alex Morgan; Vitamin Shoppe BodyTech Elite Altered Strength line sponsors Team Red, White & Blues; contract pharma/consumer health product development firm LabConnect appoints Wesley Wheeler CEO; Avanos’ Game Ready is “Recovery Partner” of NFL’s Nick Bosa; Akita adds Robert Hanson to advisory board; and BODi has wrestler as brand ambassador

PCCPs Can Help Speed Device Sterilization Changes, FDA Webinar Suggests

PCCPs Can Help Speed Device Sterilization Changes, FDA Webinar Suggests

Manufacturers looking to change their device sterilization method as part of the move away from ethylene oxide (EtO) may be able to make use of the Predetermined Change Control Plan (PCCP) process, FDA officials said in a webinar this week.